Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048583805> ?p ?o ?g. }
- W3048583805 endingPage "e129" @default.
- W3048583805 startingPage "e115" @default.
- W3048583805 abstract "Abstract The U.S. Food and Drug Administration recently approved two poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of biomarker-positive metastatic castrate resistant prostate cancer. The benefits of PARP inhibition have been well characterized in patients who have BRCA1 and BRCA2 mutations in several forms of cancer. BRCA1 and BRCA2 occupy key roles in DNA damage repair, which is comprised of several different pathways with numerous participants. Patients with mutations in other key genes within the DNA damage repair pathway may also respond to treatment with PARP inhibitors, and identification of these alterations could significantly increase the percentage of patients that may benefit from PARP inhibition. This review focuses on the potential for synthetically lethal interactions between PARP inhibitors and non-BRCA DNA damage repair genes. Implications for Practice The treatment potential of PARP inhibition has been well characterized in patients with BRCA1 and BRCA2 mutations, but there is compelling evidence for expanding the use of PARP inhibitors to mutations of other non-BRCA DNA damage repair (DDR) genes. This could increase the percentage of patients that may benefit from treatment with PARP inhibitors alone or in combination with other therapies. Understanding the significance of PARP inhibitor-sensitizing alterations in other common non-BRCA DDR genes will help guide clinical decisions to provide targeted treatment options to a wider population of patients." @default.
- W3048583805 created "2020-08-18" @default.
- W3048583805 creator A5008633297 @default.
- W3048583805 creator A5062397687 @default.
- W3048583805 creator A5067717961 @default.
- W3048583805 creator A5079418869 @default.
- W3048583805 creator A5090370478 @default.
- W3048583805 date "2020-09-08" @default.
- W3048583805 modified "2023-10-15" @default.
- W3048583805 title "PARP Inhibitors and Prostate Cancer: To Infinity and Beyond<i>BRCA</i>" @default.
- W3048583805 cites W1578291413 @default.
- W3048583805 cites W161544807 @default.
- W3048583805 cites W1940241680 @default.
- W3048583805 cites W1969458729 @default.
- W3048583805 cites W1970184435 @default.
- W3048583805 cites W1973268287 @default.
- W3048583805 cites W1977496972 @default.
- W3048583805 cites W1979543776 @default.
- W3048583805 cites W1981258136 @default.
- W3048583805 cites W1983863777 @default.
- W3048583805 cites W1984919526 @default.
- W3048583805 cites W1985479373 @default.
- W3048583805 cites W1986471561 @default.
- W3048583805 cites W1987745028 @default.
- W3048583805 cites W1994987687 @default.
- W3048583805 cites W1996931025 @default.
- W3048583805 cites W2006001375 @default.
- W3048583805 cites W2009007206 @default.
- W3048583805 cites W2009454156 @default.
- W3048583805 cites W2010053675 @default.
- W3048583805 cites W2011291904 @default.
- W3048583805 cites W2015206344 @default.
- W3048583805 cites W2022502148 @default.
- W3048583805 cites W2051184323 @default.
- W3048583805 cites W2059365987 @default.
- W3048583805 cites W2068087390 @default.
- W3048583805 cites W2077436902 @default.
- W3048583805 cites W2086038769 @default.
- W3048583805 cites W2092950132 @default.
- W3048583805 cites W2098737737 @default.
- W3048583805 cites W2102317602 @default.
- W3048583805 cites W2104566573 @default.
- W3048583805 cites W2108192712 @default.
- W3048583805 cites W2111033000 @default.
- W3048583805 cites W2114843025 @default.
- W3048583805 cites W2119346494 @default.
- W3048583805 cites W2120365943 @default.
- W3048583805 cites W2123814549 @default.
- W3048583805 cites W2129116440 @default.
- W3048583805 cites W2131593373 @default.
- W3048583805 cites W2134536765 @default.
- W3048583805 cites W2135409663 @default.
- W3048583805 cites W2136962425 @default.
- W3048583805 cites W2137334007 @default.
- W3048583805 cites W2139322091 @default.
- W3048583805 cites W2142629844 @default.
- W3048583805 cites W2145583284 @default.
- W3048583805 cites W2149441684 @default.
- W3048583805 cites W2153466677 @default.
- W3048583805 cites W2155206680 @default.
- W3048583805 cites W2156391988 @default.
- W3048583805 cites W2158546639 @default.
- W3048583805 cites W2161112598 @default.
- W3048583805 cites W2167844213 @default.
- W3048583805 cites W2171972386 @default.
- W3048583805 cites W2201330717 @default.
- W3048583805 cites W2212776653 @default.
- W3048583805 cites W2235405584 @default.
- W3048583805 cites W2325814368 @default.
- W3048583805 cites W2339471430 @default.
- W3048583805 cites W2462985846 @default.
- W3048583805 cites W2465485650 @default.
- W3048583805 cites W2471011913 @default.
- W3048583805 cites W2539944286 @default.
- W3048583805 cites W2587333476 @default.
- W3048583805 cites W2594301310 @default.
- W3048583805 cites W2597062310 @default.
- W3048583805 cites W2610575140 @default.
- W3048583805 cites W2612428976 @default.
- W3048583805 cites W2620706965 @default.
- W3048583805 cites W2625362849 @default.
- W3048583805 cites W2789900707 @default.
- W3048583805 cites W2792729825 @default.
- W3048583805 cites W2796336849 @default.
- W3048583805 cites W2797944248 @default.
- W3048583805 cites W2800410357 @default.
- W3048583805 cites W2803857309 @default.
- W3048583805 cites W2808021061 @default.
- W3048583805 cites W2810583998 @default.
- W3048583805 cites W2885844784 @default.
- W3048583805 cites W2888002479 @default.
- W3048583805 cites W2896490588 @default.
- W3048583805 cites W2901011044 @default.
- W3048583805 cites W2902324525 @default.
- W3048583805 cites W2902703786 @default.
- W3048583805 cites W2904660559 @default.
- W3048583805 cites W2911653212 @default.
- W3048583805 cites W2914260707 @default.